Ken Griffin Clene Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$0.31 - $0.44 $1,550 - $2,200	5,000 Added 333.33%	6,500 $2,000
Q1 2024 May 15, 2024	SELL	$0.28 - $0.53 $4,536 - $8,586	-16,200 Reduced 91.53%	1,500 $0
Q4 2023 Feb 14, 2024	SELL	$0.26 - $0.55 $52 - $110	-200 Reduced 1.12%	17,700 $5,000
Q3 2023 Nov 14, 2023	SELL	$0.46 - $0.87 $1,150 - $2,175	-2,500 Reduced 12.25%	17,900 $8,000
Q2 2023 Aug 14, 2023	SELL	$0.78 - $1.22 $9,984 - $15,616	-12,800 Reduced 38.55%	20,400 $17,000
Q1 2023 May 15, 2023	BUY	$0.95 - $1.62 $9,215 - $15,714	9,700 Added 41.28%	33,200 $37,000
Q4 2022 Feb 14, 2023	SELL	$0.92 - $40.2 $58,972 - $2.58 Million	-64,100 Reduced 73.17%	23,500 $23,000
Q3 2022 Nov 14, 2022	BUY	$0.33 - $73.0 $28,908 - $6.39 Million	87,600 New	87,600 $245,000

230K

25K

Ticker CLNN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,502,000
Market Cap $273M
Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.